source
- MPM BioImpact adds three China-origin drug programs to K2 Therapeutics portfolioMPM BioImpact, a biotech investment firm, is intensifying its "best of both worlds" approach by bringing drug candidates that originated in China to a broader market. Over the past year its portfo…
- Pfizer settles with generics to extend tafamidis patent until 2031, protecting revenuePfizer announced settlements with three generic manufacturers-Dexcel Pharma, Hikma Pharmaceuticals and Cipla-to delay the launch of generic versions of tafamidis, the active ingredient in its rare‑…